Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

US11964015B2 · kind B2 · utility

Assignees

• Deutsches Krebsforschungszentrum · DE
• RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

• Barbara Leuchs · Heidelberg, DE
• Antonio Marchini · Heidelberg, DE
• Jean Rommelaere · Heidelberg, DE
• Assia Angelova · Heidelberg, DE
• Dirk Jager · New York, US
• Wolfgang Wick · Heidelberg, DE
• Michael Dahm · Munich, DE

Key dates

• Filing date: Apr 9, 2021
• Grant date: Apr 23, 2024
• Expiry date: Nov 28, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14332
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.